

Neuropathologie WiSe 24/25

Neurodegenerative Erkrankungen

Prof. Dr. Ruth Stassart

Paul-Flechsig-Institut - Zentrum für Neuropathologie und Hirnforschung




- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson

- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson


Was sind neurodegenerative Erkrankungen?

Was sind neurodegenerative Erkrankungen?

- Progrediente neuronale Dysfunktion und neuronaler Verlust
- Sehr unterschiedliche Definitionen und Klassifikationen




Wilson et al., Cell 2023



Wilson et al., Cell 2023

Klinisch:
Demenz vs
Motorische Störung



Wilson et al., Cell 2023

Klinisch: Demenz vs Motorische Störung

Movement disorders
Akinetic and rigid
Hyperkinetic
Ataxic
Motor neuron disorders
Cognitive disturbance (dementia)
Temporal and parietal degenerations
Frontotemporal degenerations
Multifocal degenerations

Selektiver Nervenzellverlust in Neurodegeneration

M. Alzheimer (AD)

M. Parkinson (PD)

Frontotemporale Demenz (FTD)


Chorea Huntington (HD)

Amyotrophe

Lateralsklerose (ALS)


Spinale Muskelatrophie (SMA)

Spinocerebelläre Ataxien (SCA)
und andere



Gan, L., Cookson, M.R., Petrucelli, L. et al. (2018) Nat Neurosci 21, 1300–1309


Neurodegenerative Erkrankungen: Aggregopathien





Alzheimer's plaques and tangles




Parkinson's Lewy bodies




Huntington's intranuclear inclusions




Prion amyloid plaques



Amyotrophic lateral sclerosis aggregates




Was sind neurodegenerative Erkrankungen?




Was sind neurodegenerative Erkrankungen?

NDD hallmarks at the subcellular level



Wilson et al., Cell 2023

- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson



Auguste Deter: 1850-1906

„Über eine
eigenartige
Erkrankung der
Hirnrinde“

Klinik:
Zeitlich-/räumlicher Orientierungsverlust
Vergesslichkeit, Aphasie, Paraphrasien

Demenz nach ICD 10:

Störung des Gedächtnisses und mindestens einer weiteren kognitiven Teilleistung
Länger als 6 Monate anhaltend
Chronisch progredient
Bewusstseinsstörung muss ausgeschlossen sein
Störung der sozialen und/oder beruflichen Funktion

Ursachenspektrum
demenzielles Syndrom

Primär neurodegenerativ:

M. Alzheimer >50 % aller Demenzen
Frontotemporale Demenz
M. Parkinson
Lewy-Body-Demenz
Chorea Huntington
Progressive nukleäre Blickparese
Vaskulär ~ 20% aller Demenzen


Sekundär z.B.:

Hypox. Hirnschaden
Tumor/Blutung/Trauma
Entzündlich
Metabolisch/ Toxisch
Normaldruckhydrozephalus





nicht jedes demenzielle Syndrom ist durch eine neurodegenerative Erkrankung bedingt


Neurodegenerative Erkrankungen gehen häufig mit demenziellem Syndrom einher




Äußere und innere- Hirnatrophie




<https://neuropathology-web.org/chapter9/chapter9bAD.html#ad>






**Intrazelluläre
neurofibrilläre Tangles
(NFT)**




**Extrazelluläre
Neuritische
Plaques (NPs)**



**Intrazelluläre
neurofibrilläre Tangles
(NFT)**




**Extrazelluläre
Neuritische
Plaques (NPs)**




**Extrazelluläre
Neuritische
Plaques (NPs)**

Amyloidablagerungen





**Extrazelluläre
Neuritische
Plaques (NPs)**




APP = transmembranöses Glykoprotein
Gen auf Chromosom 21


Funktion unklar > Oberflächenrezeptor mit
Funktionen in der Zell-Zell und Zell-Matrix Interaktion

Amyloidablagerungen






Aβ Peptid Fragmente: insb. 40 oder 42 Aminosäuren lang. Aβ Peptide in Plaques: hauptsächlich 42-residue Form of Aβ (Aβ42)











Plaque stages: poor correlation with clinical severity of dementia



Stage A: Low density of plaques in neocortex, especially frontal, temporal and occipital lobes



Stage B: Plaques present in neocortical association areas with moderate hippocampal involvement





Stage C: Plaques present in primary sensory and motor areas in addition to other cortical areas


Mild

Moderate


Severe











**Intrazelluläre
neurofibrilläre Tangles
(NFT)**




**Extrazelluläre
Neuritische
Plaques (NPs)**






Early stage: There is accumulation of tau protein in neurons but in a dispersed form detectable only by immunohistochemistry for tau protein. There may be perinuclear accentuation of immunoreactivity. Silver staining does not reveal any abnormality.



Established stage: Tau protein is aggregated into paired helical filaments as well as a smaller number of straight filaments. There is ubiquitination of some of the tau protein in tangles rendering them immunoreactive for ubiquitin. Silver staining reveals classical tangles.

Late stage: There is death of the neuron and removal of cell debris by local phagocytes. The tangle structure remains as an eosinophilic extracellular 'tombstone' or ghost tangle. With time there is progressive loss of tau-protein immunoreactivity. A β -peptide is later deposited around these structures as amyloid, and there is infiltration by astroglial processes making these NFTs apparently immunoreactive for GFAP.



Tau protein
 Neuron
 A β


Biologie des Tau-Proteins

Tau-Protein:
Mikrotubuli- assoziiertes Protein
und wichtig für die Funktionalität
des Zytoskeletts

M. Alzheimer: Tau-Protein
hyperphosphoryliert

Verdrängung von Zellorganellen
axonaler Transport ↓
Zytoplasmatische Zirkulation ↓



Tangle stages: good correlation with clinical severity ratings



TRANSENTORHINAL
(Clinically asymptomatic)

Stage I: NFTs and NTs in small density, confined to transentorhinal cortex in pre- α cells.

Stage II: Tangles present in moderate density in pre- α cells of entorhinal cortex. Small numbers develop in CA1 region of hippocampus




LIMBIC
(Incipient AD)

Stage III: There are modest numbers of NFTs and NTs throughout CA1 and in pyramidal cells in the subiculum. Small numbers appear in the fusiform gyrus lateral to the transentorhinal cortex as well as in the nucleus basalis of Meynert and amygdaloid complex.

There is now severe involvement of pre- α cells with neuronal loss and gliosis


Stage IV: Severe involvement of areas affected in stage 3. Large numbers of ghost tangles in entorhinal and transentorhinal regions. Mild involvement of isocortex with sparing of primary sensory and motor cortices.




ISOCORTICAL
(Symptomatic AD)

Stage V: Tangles in all sectors of hippocampus and subiculum. Widespread, moderate to severe isocortical involvement but still relative sparing of primary sensory and motor cortices. Tangles in claustrum, thalamus, hypothalamus. Ghost tangles with neuronal loss and astrocytic gliosis involving pre- α cells, CA1, antero-dorsal thalamic nucleus.

Stage VI: Increased densities of tangles in regions affected in earlier stages. Tangles in dentate granule cell layer. Marked involvement of claustrum, thalamus, hypothalamus, substantia nigra



**Extrazelluläre
Neuritische
Plaques (NPs)**



**Intrazelluläre
neurofibrilläre Tangles
(NFT)**

Gemeinsame Endstrecke:
Neuronale Degeneration/ Untergang, Verlust von Synapsen, Hirnatrophie,
Hydrocephalus e vacuo

Genetik

Early onset (vor dem 65. Lebensjahr)

Selten (~7%) und oft familiär

Mutationen im APP (Amyloid Precursor Protein) (21q)


Mutationen in PSN1 (Presenilin 1) (14q23.3)




Mutationen in PSN2 (Presenilin 2) (1q13)

Late onset (nach dem 65. Lebensjahr)




Häufig und nicht familiär

APOE e4 (19q13.2)







- Klinische Symptomatik
 - äußere- und innere Hirnatrophie, verm. Hirngewicht
 - Extrazelluläre Ablagerung von neuritischen Plaques; (NPs) Cerebrale Amyloidangiopathie (CAA)
 - Intrazelluläre Akkumulation von Tau-Protein in Form von neurofibrillären Tangles (NFT)
 - Neuronaler Degeneration und Nervenzellverlust, Gliose, granulovakuoläre Degeneration, Hirano-Körperchen




Postmortale Diagnostik kann zur Ursachenklärung der klinischen Symptomatik beitragen

- Überblick zu neurodegenerativen Erkrankungen
- Typische histomorphologische Merkmale des M. Alzheimer
- Typische histomorphologische Merkmale des M. Parkinson




- Handwritten signature* 1809
- Handwritten signature* 1824
- Handwritten signature* 1827
- Handwritten signature* 1830
- Handwritten signature* 1831
- Handwritten signature* 1834

https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.uimmed.de%2Fimages%2Fdownload%2Fthema_des_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8iRuuJQJFhTR6_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=CCAGQxqf'wOTGik3CSanuDQGA AAAAAdAAAAAD
https://www.t-online.de/sport/boxen/id_78028822/nod-von-muhammad-ali-sprecher-nennt-die-todesursache.html



Tremor
Rigor
Akinetik
Posturale Instabilität



- Handwritten signature* 1809
- Handwritten signature* 1824
- Handwritten signature* 1827
- Handwritten signature* 1830
- Handwritten signature* 1831
- Handwritten signature* 1834


Epidemiologie: Häufigkeitsgipfel 50.-60. Lebensjahr, m=f, zu 70% idiopathisch

https://www.google.de/url?sa=i&url=http%3A%2F%2Fwww.nlm.nih.gov%2Fimg%2Fdownload%2Fimg_des_monats%2FParkinson-1-Krankheit.pdf&psig=AOvVaw0yBkPZ8RuuJQJFhTR6_1NQ&ust=169641135695400&source=images&cd=1&ek=ves=DCAJQjxqf'wot'Gik%3D&asudCFQAAAAAABAD
https://www.t-online.de/sport/boxen/id_78028822/nod-von-muhammad-ali-sprecher-nennt-die-todesursache.html



Verlust neuromelaninhaltiger dopaminerges
Neurone der Substantia nigra

Pathophysiologie des M. Parkinsons




Hemmende Wirkung der SN auf die Basalganglienschleife entfällt



Enthemmte Basalganglienschleife hemmt den Thalamus


Autonome Störungen (Vaguskerne, sympathische Ganglien)

Basalganglienschleife
 D1 Aktivierung : Direkter Weg
 D2 Aktivierung und Hemmung des STN: Indirekter Weg



https://de.wikipedia.org/wiki/Parkinson-Krankheit#/media/Datei:Parkinson_-_Ablauf_auf_funktioneller_Ebene.svg







3 Synucleine:

α -Synuclein (chr.4)
 β -Synuclein (chr.5)
 γ -Synuclein (chr.10)

α -Synuclein als synaptisches lösliches Protein in Nervenzellen, Bildung von Membrankanälen, Regulation der Dopaminausschüttung

→Lewy-Körperchen,
neurotoxische Wirkung,
Nervenzelluntergang






- Ausgeprägter Verlust melanin-
pigmentierter, dopaminerg
Nervenzellen in der Substantia nigra



- Konzentrische hyaline Einschlüsse
(Lewy-Körper) in den pigmentierten
Nervenzellen.



- Gliose und melaninhaltige
Makrophagen



Genetische Formen

Idiopathisches (M. Parkinson)

Sekundäre Parkinsonsyndrome



-Medikamente: typ.
Antipsychotica, Lithium,
Valproat, Metoclopramid
- Traumatisch, Tumor, toxisch
(CO, Mangan), metabolisch
(M.Wilson)

Atypische Parkinsonsyndrome

Multisystematrophie
Lewy-Body-Demenz
Progressive supr. Blickparese
Kortikobasale Degeneration

Postmortale Diagnostik zur
Diagnosesicherung und/oder
weiteren Einordnung

Synukleinopathien

Lewy Body Erkrankungen

Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs ≥ 1 year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia

Epidemiologie:

Prävalenz 0,4% der über 65 jährigen
Häufigstes atypisches Parkinsonsyndrom

Klinik:

Bradykinese/Rigor mit
führend neuropsychiatrische Symptome:
fluktuierend kognitive Defizite
akustische/visuelle Halluzinationen
Wahnhafte Episoden
Depression und Angststörung




Synukleinopathien

Lewy Body Erkrankungen

Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs ≥ 1 year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia

Multisystematrophie

Gliale Einschlüsse von alpha-Synuklein



Synukleinopathien

Lewy Body Erkrankungen


Disorder	Main site of Lewy body pathology	Clinical correlate
Parkinson's disease (PD)	Substantia nigra	Akinetic-rigid syndrome
Parkinson's disease with dementia (PDD)	Substantia nigra, cerebral cortex	Dementia occurs ≥ 1 year after a clinical diagnosis of PD
Dementia with Lewy bodies (DLB)	Cerebral cortex, substantia nigra	Dementia with akinetic-rigid syndrome. Dementia occurs within a year of onset of parkinsonian features
Autonomic failure	Sympathetic neurons in spinal cord	Autonomic failure
Lewy body dysphagia	Dorsal vagal nucleus	Dysphagia







Multisystematrophie

Gliale Einschlüsse von alpha-Synuklein

MSA – P: Parkinson Symptomatik im Vordergrund
 MSA – C: cerebelläre Symptomatik im Vordergrund

Olivopontocerebellar atrophy (OPCA)
 Shy-Drager syndrome
 Striatonigral degeneration.




	α -syn strains	leading α -syn inclusion pathology	main areas of neuronal loss
classical α -synucleinopathies	PD 	LB 	 - substantia nigra pars compacta
	DLB 	LB 	 - neocortex - substantia nigra pars compacta
	MSA 	GCI 	 - SND - OPCA - brainstem nuclei - autonomic nuclei in the spinal cord

Die Herausforderung der Neurodegenerativen Erkrankungen

Prävalenz M. Alzheimer	
65-69	1%
70-74	2%
75-79	4%
80-84	8%
über 85	20% - 50%

Altersstruktur der Bevölkerung in Deutschland, 1950–2060



* Ergebnis der aktualisierten 13. koordinierten Bevölkerungsvorausberechnung (Variante 2-A)
Datenquelle: Statistisches Bundesamt

© BiB 2018 / demografie-portal.de

Neurodegenerative Erkrankungen und Demenz 2060?

- Neurodegeneration mit abnormer Proteinablagerung assoziiert
- Neurodegenerative Erkrankungen gehen häufig mit demenziellem Syndrom einher, ABER
- Nicht jedes demenzielles Syndrom ist durch neurodegenerative Erkrankung bedingt
- Histopathologie M. Alzheimer und M. Parkinson
- Postmortale Diagnostik zur Diagnosesicherung und weiteren Einordnung

Vielen Dank für Ihre Aufmerksamkeit



Bei Fragen, Anmerkungen, Lob/ Kritik:

Ruth.Stassart@medizin.uni-leipzig.de